A

Arvinas
D

ARVN

25.800
USD
0.67
(2.67%)
Market Closed
Volume
0
EPS
-2
Div Yield
-
P/E
-5
Market Cap
1,772,797,928
OverviewSignalsIdeasNews
Related Instruments
    A
    ALLO
    -0.19000
    (-7.71%)
    2.27500 USD
    B
    BEAM
    -2.275
    (-8.65%)
    24.035 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    N
    NTLA
    -1.165
    (-7.71%)
    13.955 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    T
    TXG
    -0.785
    (-5.56%)
    13.340 USD
    V
    VYGR
    -0.57000
    (-9.18%)
    5.64000 USD
    More
News

Title: Arvinas

Sector: Healthcare
Industry: Biotechnology
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.